The Middle East & African ovarian cancer diagnostics and therapeutics market is expected to register a CAGR of 9.2% during the forecast period, 2018 to 2023. GCC is expected to dominate the market for ovarian cancer diagnostics and therapeutics due to the increasing incidence of ovarian cancer.
Increasing Incidence of Ovarian Cancer
Ovarian cancer is the sixth most common cancer among women. The annual mortality rate per 100,000 people from ovarian cancer in North Africa and Middle East has increased by 20.1% since 1990, an average of 0.9% a year. Thus, the increasing incidence of ovarian cancer is fueling the growth of the Middle East & African ovarian cancer diagnostics and therapeutics market.
Additionally, greater use of combination therapies for the treatment of ovarian cancer, increasing population of aged women, and increase in healthcare expenditure in developing countries are fueling the growth of the Middle East & African ovarian cancer diagnostics and therapeutics market.
Lack of Accurate Diagnosis of Ovarian Cancer
Accurate diagnosis for ovarian cancer is critical, as in most cases, the cancer already begins to spread to the lymph nodes and outside of the pelvis at the time of diagnosis. Ovariancancerawareness.org reports that the five-year survival rate for ovarian cancer with early stage 1 detection is 93%, and that most new cases of ovarian cancer are diagnosed at stage 3 or later, leaving little time as well as room for an accurate diagnosis. Lack of early detection and accurate diagnosis is often because ovarian cancer symptoms are frequently overlooked, and easily confused with other conditions. In addition, patent expiry of key drugs is also restraining the growth of the Middle East & African ovarian cancer diagnostics and therapeutics market.
GCC to Dominate the Market
Ovarian cancer is the 11th most common type of cancer in the GCC states. Between January 1998 and December 2004, 1,180 ovarian cancer cases were reported from all GCC states, which is 2.0% of all cancers and 4.0% of cancers among females. Bahrain reported the highest incidence of ovarian cancer. The age-standardized rate (ASR) per 100,000 women was 7.4 for Bahrain, followed by Qatar (6.7), Kuwait (5.9), Oman (5.5), UAE (4.4), and KSA (2.3).
Key Developments in the Market
- May 2017 - A new drug developed for ovarian cancer ONX-0801 is in Phase1.
The major players include - Bristol Myers Squibb Company, Eli Lilly and Company, GlaxosmithklinePlc, Janssen Pharmaceuticals, Inc., Genentech Inc., Astra Zeneca Boehringer Ingelheim and F. Hoffman-La Roche Ltd, among others.
Reasons to Purchase the Report
- Market analysis for the Middle East & Africa ovarian cancer diagnostics and therapeutics market, with region-specific assessments and competition analysis on a global and regional scale
- Analyzing various perspectives of the industry with the help of Porter’s five forces analysis
- The treatment type that is expected to dominate the market
- Regions that are expected to witness fastest growth during the forecast period
- Identify the latest developments, market shares, and strategies employed by the major market players.
- 3 month analyst support, along with the Market Estimate sheet (in Excel)
Customization of the Report
- This report can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
1. Introduction
1.1 Market Definition
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
5.1 Current Market Scenario
5.2 Porter's Five Forces
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threat of New Entrants
5.2.4 Threat of Substitute Product and Services
5.2.5 Competitive Rivalry Within the Industry
6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
6.1 Market Driver
6.1.1 Increasing Incidences of Ovarian Cancer
6.1.2 Increasing Population of Aged Women
6.1.3 Greater Use of Combination Therapies for the Treatment of Ovarian Cancer
6.1.4 Increase in Healthcare Expenditure in developing countries
6.2 Market Restraint
6.2.1 Patent Expiry of Key Drugs
6.2.2 Lack of Accurate Diagnosis of Ovarian Cancer
6.3 Opportunities
6.4 Key Challenges
7. Market Segmentation
7.1 By Cancer Type
7.1.1 Epithelial Ovarian Tumors
7.1.2 Ovarian Germ Cell Tumors
7.1.3 Ovarian Stromal Tumors
7.1.4 Primary Peritoneal Carcinoma
7.2 By Cancer Stage
7.2.1 Stage I
7.2.2 Stage II
7.2.3 Stage III
7.3 By Diagnosis
7.3.1 Physical Examination
7.3.2 Biopsy
7.3.3 Blood Tests
7.3.4 Human Chorionic Gonadotropin (HCG) Test
7.3.5 Ultrasound
7.3.6 PET
7.3.7 CT Scan
7.3.8 Others
7.4 By Treatment
7.4.1 Chemotherapy
7.4.1.1 Paclitaxel
7.4.1.2 Docetaxel
7.4.1.3 Cisplatin
7.4.1.4 Carboplatin
7.4.1.5 Others
7.4.2 Targeted Therapy
7.4.2.1 Bevacizumab
7.4.2.2 Olaparib
7.4.3 Radiation Therapy
7.4.4 Immunotherapy
7.4.4.1 Carboplatin
7.4.4.2 Paclitaxel
7.4.5 Hormonal Therapy
7.4.5.1 Goserelin
7.4.5.2 Leuprolide
7.5 By Geography
7.5.1 Middle East & Africa
7.5.1.1 GCC
7.5.1.2 South Africa
7.5.1.3 Rest of Middle East & Africa
8. Competitive Landscape
8.1 Mergers and Acquisition Analysis
8.2 Agreements, Collaborations & Partnerships
8.3 New Products Launches
9. Key Players
9.1 Astra Zeneca
9.2 Boehringer Ingelheim
9.3 Bristol Myers Squibb Company
9.4 Eli Lilly and Company
9.5 F. Hoffman-La Roche Ltd
9.6 Genentech Inc.
9.7 Glaxosmithkline Plc
9.8 Janssen Pharmaceuticals, Inc.
*List Not Exhausitive
10. Outlook of the Market
